You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


GSK’s anti-BCMA drug Blenrep wins US approval

The US Food and Drug Administration (FDA) has approved GlaxoSmithKline’s anti-BCMA therapy Blenrep (belantamab mafodotin-blmf) for the treatment of patients with relapsed or refractory multiple myeloma.